Showing all 9 results

Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1)

$9,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 96 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Keytruda (anti-PD1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1)

$9,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 96 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Keytruda (anti-PD1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1) – IMMUNE 3D

$10,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 6 days in the presence of drug candidate
  2. After 6 days harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Tecentriq (anti-PDL1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)

What readouts are included in the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehyrdogenase (LDH)  for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1) – IMMUNE 3D

$10,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 6 days in the presence of drug candidate
  2. After 6 days harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Keytruda (anti-PD1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)

What readouts are included in the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehyrdogenase (LDH)  for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Cytotoxic T cell (CTL) assay with Tecentriq (anti-PDL1)

$9,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 96 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Tecentriq (anti-PDL1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Cytotoxic T cell (CTL) assay with Tecentriq (anti-PDL1) – IMMUNE 3D

$10,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 6 days in the presence of drug candidate
  2. After 6 days harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Tecentriq (anti-PDL1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)

What readouts are included in the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehyrdogenase (LDH)  for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Keytruda Resistant TIL and Tumor co-culture

$9,000.00

Description

Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that  play various roles in the immune-tumor interactions.  TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).

Using our Keytruda resistant TIL and Tumor cell line, this assay attempts to screen drug candidates in comparison with Keytruda (anti-PD1) therapy.

What is the assay setup?

  1. Co-culture tumor and TIL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. TIL + Tumor+ Keytruda (anti-PD1)
  2. TIL + Tumor+ <drug candidate (per dose)>
  3. TIL + Tumor
  4. TIL + Tumor + DMSO
  5. TIL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Keytruda Resistant TIL and Tumor co-culture – IMMUNE 3D

$9,000.00

Description

Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that  play various roles in the immune-tumor interactions.  TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).

IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay uses our Keytruda resistant TIL and Tumor cell line in comparison with Keytruda (anti-PD1) therapy and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and TIL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. TIL + Tumor+ Keytruda (anti-PD1)
  2. TIL + Tumor+ <drug candidate (per dose)>
  3. TIL + Tumor
  4. TIL + Tumor + DMSO
  5. TIL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehydrogenase (LDH) for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Keytruda Sensitive TIL and Tumor co-culture

$9,000.00

Description

Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that  play various roles in the immune-tumor interactions.  TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).

Using our Keytruda sensitive TIL and Tumor cell line, this assay attempts to screen drug candidates in comparison with Keytruda (anti-PD1) therapy.

What is the assay setup?

  1. Co-culture tumor and TIL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. TIL + Tumor+ Keytruda (anti-PD1)
  2. TIL + Tumor+ <drug candidate (per dose)>
  3. TIL + Tumor
  4. TIL + Tumor + DMSO
  5. TIL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.